Form 4: Cytokinetics Director Lynne Parshall Executes Option and Sells Shares
SEC Form 4 Filing
Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on August 26, 2024.
Summary
- On August 26, 2024, Lynne Parshall, a director of Cytokinetics Inc., executed a transaction involving the company's stock.
- Parshall exercised a non-qualified stock option to purchase 5,000 shares of common stock at a price of $21.61 per share.
- Simultaneously, Parshall sold 5,000 shares of common stock at a price of $57.26 per share.
- Following these transactions, Parshall directly owns 20,600 shares of Cytokinetics Inc.
- Parshall also holds options for 5,000 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 08/26/2024 | Date of transaction: Lynne Parshall exercised stock options and sold shares. |
| 05/13/2030 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.